Overview
Cardiologs offers a medical-grade AI platform that analyzes ECGs to help clinicians diagnose cardiovascular diseases. The system automatically detects more than 20 arrhythmia types and provides clinically validated results to improve diagnostic accuracy. Clinicians upload ECG data, the AI processes the signals, and generates reports that fit into standard clinical workflows; the service runs on a subscription model for healthcare institutions and professionals. Its emphasis on clinical validation, automated analysis, and seamless integration into digital health workflows sets it apart and aims to improve patient care worldwide.
Work here?Claim your company
Simplify's Take
What believers are saying
- Philips deployed ePatch in Spain during May 2024 using Cardiologs analytics.
- FDA approvals for cardiac AI surpassed 145 by June 2026, validating the category.
- Western Europe demand for cloud ECG analysis keeps Cardiologs positioned inside Philips' distribution network.
What critics are saying
- Philips now controls Cardiologs; corporate prioritization can starve standalone innovation by 2027.
- Philips ECG AI Marketplace, launched July 2025, commoditizes Cardiologs against Anumana and others.
- iRhythm, Boston Scientific, and GE HealthCare outspend Philips in cardiac diagnostics.
What makes Cardiologs unique
- Philips acquired Cardiologs in 2021, embedding it into a global cardiac portfolio.
- Cardiologs' deep-learning ECG software remains vendor-neutral across Holter, patch, and smartwatch data.
- Its algorithms analyze over 20 million ECG recordings, supporting broad arrhythmia detection.
Help us improve and share your feedback! Did you find this helpful?